EMA Critical Comments on Patient-Reported Outcomes in European Drug Approvals

European Medicines Agency assessments of new drug applications continue to point to shortcomings captured in EMA critical comments on patient-reported outcomes, particularly around trial design and analytic rigor between 2020 and 2023.

Reviewer feedback from the European Medicines Agency identifies persistent vulnerabilities in trial architecture, analytic procedures, and data completeness for patient-reported outcome data submitted for new indications. These concerns do not automatically block incorporation into product labeling when endpoints receive multiplicity adjustment. Oncology submissions attract design-related critiques more frequently than non-oncology applications, whereas positive remarks on measure selection and statistical planning align with higher rates of documented treatment effects.

Extraction and Coding Approach 

All new active substances recommended for approval during the four-year window were identified, with non-novel agents and diagnostic products excluded. Public assessment reports, summaries of product characteristics, and package leaflets for each retained indication underwent structured extraction of patient-reported outcome details from confirmatory trials. A coding scheme refined through dual independent review enabled classification of comments into critical or supportive categories and thematic grouping around study architecture and statistical handling.

Ad

Therapeutic Area Differences

Confirmatory trials incorporated patient-reported outcome measures in three-quarters of the 167 indications examined, prompting agency commentary on two-thirds of those submissions. Design concerns accounted for nearly half of all critical remarks and predominated in oncology, often citing open-label or single-arm structures that weaken causal attribution. Statistical critiques ranked second in frequency and more commonly targeted non-oncology submissions lacking multiplicity protection or prespecified missing-data strategies.

Path Forward for Sponsors

Manufacturers can improve prospects for inclusion of patient-reported outcome statements in official labeling by embedding such endpoints within multiplicity-controlled hierarchies and documenting prespecified handling of incomplete observations. The recent draft reflection paper on patient experience data signals an institutional shift toward explicit documentation of how these measures inform regulatory judgments. Proactive alignment of trial protocols with agency expectations on blinding, endpoint prioritization, and clinical relevance thresholds will materially influence acceptance of patient-centered evidence in European value messaging.